DP
ABBV icon

DDD Partners’s AbbVie ABBV Stock Holding History

DDD Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.9M Buy
91,397
+2,757
+3% +$612K 1.37% 20
2025
Q4 		$20.3M Buy
88,640
+234
+0.3% +$53.3K 1.29% 21
2025
Q3 		$20.5M Sell
88,406
-18,274
-17% -$3.72M 1.3% 16
2025
Q2 		$19.8M Sell
106,680
-5,843
-5% -$1.09M 2.12% 20
2025
Q1 		$23.6M Sell
112,523
-12,822
-10% -$2.49M 2.86% 10
2024
Q4 		$22.3M Buy
125,345
+11,168
+10% +$2.05M 2.74% 12
2024
Q3 		$22.5M Buy
114,177
+507
+0.4% +$94.6K 2.45% 16
2024
Q2 		$19.5M Buy
113,670
+365
+0.3% +$60.5K 2.26% 17
2024
Q1 		$20.6M Sell
113,305
-19,002
-14% -$3.27M 2.52% 13
2023
Q4 		$20.5M Sell
132,307
-822
-0.6% -$120K 2.76% 12
2023
Q3 		$19.7M Sell
133,129
-2,544
-2% -$373K 2.85% 8
2023
Q2 		$18.3M Buy
135,673
+134,327
+9,980% +$19.7M 2.53% 16
2023
Q1 		$215K Buy
1,346
+5
+0.4% +$764 0.03% 75
2022
Q4 		$217K Buy
+1,341
New +$206K 0.03% 73

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DDD Partners's ABBV Position: Q1 2026 in Review

DDD Partners increased its AbbVie (ABBV) stake by 3.1% in Q1 2026, buying an estimated $612K and bringing the position to 91,397 shares worth $19.9M. The position accounts for 1.37% of the portfolio, ranked #20.

DDD Partners first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $23.6M in Q1 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • DDD Partners held 91,397 shares of AbbVie worth $19.9M as of Q1 2026.
  • DDD Partners bought 2,757 AbbVie shares in Q1 2026, an estimated $612K.
  • AbbVie made up 1.37% of DDD Partners's portfolio in Q1 2026, its #20 holding.
  • DDD Partners first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • DDD Partners's AbbVie position peaked at $23.6M in Q1 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on DDD Partners's 13F filing for Q1 2026, filed 28 Apr 2026.